Paul Wuh-Liang Hwu, MD, PhD, on Questions Remaining With AADC Deficiency

Video

Upstaza has been granted marketing authorization by the European Commission.

"In AADC deficiency, we’re working with patients, we’re working on mice, and trying to really dig into the pathogenesis, especially in younger patients, what exactly happens to the brain without dopamine... we need to learn more about what separates responders from non-responders.”

PTC Therapeutics’ eladocagene exuparvovec (PTC-AADC; Upstaza) has been granted marketing authorization by the European commission as the first disease-modifying, genetic therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.1

Data from phase 1/2 clinical trials of Upstaza (NCT01395641; NCT02926066) demonstrated that treated patients reached clinically meaningful developmental milestones not seen in the natural history of the disease.2 Cognitive and motor skill improvements have persisted for up to 10 years after treatment.

CGTLive spoke with study investigator Paul Wuh-Liang Hwu, MD, PhD, professor, National Taiwan University Hospital, about Upstaza as well as his work in Pompe disease and spinal muscular atrophy. He discussed how there is still more to learn about AADC deficiency and challenges in treating rare diseases.

REFERENCES
1. Upstaza™ granted marketing authorization by European Commission as first disease-modifying treatment for AADC deficiency. News release. PTC Therapeutics. July 20, 2022. https://ir.ptcbio.com/news-releases/news-release-details/upstazatm-granted-marketing-authorization-european-commission
2. Tai CH, Lee NC, Chien YH, Byrne BJ, Muramatsu SI, Tseng SH, Hwu WL. Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency. Mol Ther. 2022;30(2):509-518. doi:10.1016/j.ymthe.2021.11.005
Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
© 2025 MJH Life Sciences

All rights reserved.